Every RAD 140 before and after account links RAD140 with a rise in body weight and strength, and no study has measured how much of that rise is muscle tissue or how much of it survives the end of exposure. RAD140 is a selective androgen receptor modulator (SARM), a nonsteroidal compound acting on the androgen receptor inside cells.
The accounts have a shape of their own: self-reported body weights, photographs and lifted loads, recorded while a calorie surplus, training or other compounds were in play, so no part of the change can be assigned to RAD140 alone. The measured record is smaller and different. Animal studies show the compound enlarging muscle fibres in rats and, in older male mice, preserving fat-free mass, the body’s non-fat tissue measured as lean mass. Case reports, published accounts of single patients, describe severe drug-induced liver injury after weeks to months of exposure.
Behind both sits the preclinical work that introduced the compound later known as vosilasarm, characterised it in rats and monkeys, and described it as potent and orally bioavailable. That history, and the RAD 140 mechanism of action it first set out, is the background to every later measurement, and the question does RAD 140 work comes down to whether the measured data bear out the changes the accounts describe.
This article sets the animal measurements, the case reports and the laboratory analyses of products and urine samples beside the self-reported accounts, for skeletal muscle mass, strength and what remains after exposure ends. Dose and co-administration with other compounds have their own pages.
Patients treated in hospital after muscle-building supplements
Six published case reports belong beside the photographs, and the table below holds them: young men, products containing RAD140 and sold as muscle-building supplements, hospital after weeks to months of exposure, and in every case the liver. The briefest exposure in the table belongs to the first man, who presented with cholestatic liver injury marked by impaired bile flow; a biopsy supported the diagnosis of RAD-140 liver injury, and his total bilirubin rose to the peak the table gives.
Six published RAD140 liver cases
Patient
Exposure
Injury
Peak bilirubin
Course after stopping
Man, 24
RAD-140, 5 weeks
Cholestatic liver injury, supported by biopsy
38.5 mg/dL total
Symptoms and liver injury resolved
Man, 26
RAD140, duration not given
Idiosyncratic drug-induced liver injury with jaundice
Not given
Liver panel normal at 2-month follow-up, no recurrence
Man, 29
RAD-140, 3 months
Jaundice, raised liver enzymes, fatty liver on ultrasound
Not given
Symptoms resolved
Man, 22
RAD-140, 16 weeks
Drug-induced liver injury with cholestasis on biopsy
530 µmol/L total
Bilirubin 188 µmol/L at 1 month; enzymes normal 3 to 12 months after stopping
Severe cholestatic injury, pancreatitis, acute kidney injury
Not given; kept rising
Bilirubin rose despite stopping and corticosteroids; plasmapheresis and intensive care
The third man in the table, exposed for longer, developed jaundice together with raised liver enzymes (ALT, AST, alkaline phosphatase), and ultrasound showed fatty liver. The fourth man, exposed for longer still, reached the total bilirubin peak the table gives for him.
The most severe case followed a supplement containing RAD-140 and andarine (S-4), another nonsteroidal SARM: in intensive care it brought pancreatitis and acute kidney injury and required plasmapheresis, the exchange of blood plasma to remove circulating substances. Other organs appear in the series too, possible acute myocarditis, inflammation of the cardiac muscle, in a young man, and splenic rupture in a 54-year-old man exposed to RAD-140 and MK-677 (ibutamoren, a growth hormone secretagogue), though its authors call that link speculative. LiverTox, the National Institutes of Health database of drug-induced liver injury monographs, lists the cholestatic pattern for the SARM class. What these reports record is what exposure to such products brought for these patients, and that is why they stand next to the photographs.
What before-and-after reports describe for muscle and body weight
Outside the published trials, no question recurs through the before-and-after accounts of RAD 140 more than how much of a rise in body weight is skeletal muscle mass. Most claims of a “RAD 140 muscle gain” rest on such reports, which differ widely in the cause they assign to the change. Two of the changes they describe have names: vascularity, the greater visibility of superficial veins beneath thin subcutaneous fat, and body recomposition, a fall in fat mass alongside a rise in lean mass while energy consumption stays unchanged. They describe these changes:
a marked rise in body weight over several weeks
a fuller appearance, with the shoulders said to change first
a drier look, with vascularity
body recomposition
the opposite course: body weight falling while a food surplus is maintained, and lean mass lost rather than gained
less change in later periods of exposure than in the first
body weight holding steady while striations become visible, a pattern that recurs often enough to be named, with the appearance changing while the scale stays still
In those accounts the claims rest on photographs that need their own reading. A RAD 140 transformation is typically documented in mirror shots taken at different times of day, and the images differ in lighting, in pose and in pump, the temporary swelling of muscle tissue after training; accounts collected from RAD-140 Reddit and YouTube describe the same physique as looking substantially different within a single day.
How much of the weight gained is muscle and how much is water?
Beyond the trial data, a substantial part of the weight gained is described as food and fluid rather than muscle tissue, and the fluid as water retention (held in the tissues and the circulation rather than in muscle protein); such retention is described as showing visibly after days of a high-carbohydrate diet, with scale weight changing within a week.
In descriptions beyond the trials, body weight sometimes rises with no visible change at all. RAD-140 is described, outside the trial record, as bringing a leaner, drier gain than LGD-4033 and other SARMs, which implies less fluid and so a smaller share of the weight that disappears afterwards; a fall in scale weight soon after exposure ends is widely described, and fluid leaving first is the explanation given.
Among the effects described outside the trials the measures relied on are scale weight and the mirror, and neither can settle the composition of the weight itself, because neither separates the components that move together with muscle mass:
glycogen and its bound water
fat mass
connective tissue
blood volume
In those accounts one detailed exception cites a DEXA scan, a dual-energy X-ray absorptiometry body-composition measurement, which partitioned the weight gained so that muscle tissue made up the smaller part. The exception proves the rule: the accounts of SARM RAD140 found most often give a single figure for body weight and nothing else.
How much stronger did you get?
For a trained adult the rise in strength with a SARM is generally held to be modest in absolute terms, roughly a few repetitions or one load increment per lift, and to arrive within the first weeks rather than months; accounts outside the published studies describe it as the earliest change.
The usual answer to how strong is RAD 140 takes that early rise apart. Much of it is held to be neural and technical, because better motor-unit recruitment, familiarity with the lift and confidence under load all follow training alone. A second part is attributed to recovery, because delayed-onset muscle soreness (DOMS), which peaks a day or two after unfamiliar loading, settles sooner and lets training volume rise, which is widely held to raise strength by itself. A third part is held to come from the fluid and glycogen content of muscle tissue, which supports force output while present and leaves when exposure ends.
Why does strength drop for some people on RAD140?
Outside the trial record, a fall in strength is described as a consequence of testosterone suppression, the decline in endogenous testosterone production that follows exposure to an androgen receptor agonist and that the human trial data on RAD140 and testosterone record. The fall is described as arriving partway through a period of exposure rather than at its start, and as coming with tiredness, poor sleep, lethargy, cramping and low drive; the attribution to suppression rests on the descriptions themselves, not on any measurement.
In those accounts the same drop has other explanations as well, four causes in all:
testosterone suppression, the explanation just given
very long and very frequent training sessions, because training volume was raised beyond what recovery allowed on the assumption that recovery had become faster
a calorie deficit during a period of deliberate fat loss, with strength falling as dietary energy fell
doubt about what the product actually contained, the last explanation offered, once the others have been exhausted
How soon the changes are described
Accounts outside the published studies describe a change in strength within the first days of exposure and a fuller appearance within the first weeks. Most of them pair a photograph from before exposure with one at 1 month of RAD 140, so the interval they fix reflects when change is looked for rather than when it occurs.
Outside the trial record, testolone is described as producing visible change in the shoulders and upper arms before other regions, and the one-month pairing is built around that early shift, though not every account follows that course; among the effects described outside the trials, the absence of any visible change by the third week recurs often enough to raise a question of its own, whether anything is to be expected within three weeks.
In those accounts rapid early change is sometimes put down not to the compound but to skeletal muscle memory, the faster regain of previously held muscle mass after a period without training. The accounts in question describe a return to training after a break, following an earlier period of greater lean mass, and they are the hardest of all to interpret, because the rate of regain after detraining is steep without any exposure to the compound.
Could I have made these gains without RAD-140?
Yes, as a rule. Such a change is generally held to be achievable without RAD-140: a food surplus, progressive training and the faster regain of earlier muscle mass explain most of what is described over a typical eight to twelve weeks of exposure, and two starting points add to them. The five are:
a calorie surplus, food energy above daily expenditure, widely understood to be the necessary condition for a rise in lean mass
progressive overload, the steady increase in load or volume across sessions, commonly described as the stimulus that then directs that surplus towards muscle tissue rather than fat mass
the faster regain of earlier muscle mass, because previously trained muscle tissue retains additional myonuclei from earlier hypertrophy, so regain is generally held to run several times faster than initial growth
a start after a break from training
a start with a first serious attempt at structured training
With a surplus and progressive overload both present, a rise of one to two pounds a month in lean mass is generally held to be achievable in a trained adult male without any compound, considerably more in an untrained one, and more again in previously trained muscle tissue. Beyond the trial data, the periods of exposure described most often begin from one of the last two starting points, the two that carry the highest baseline rate of change.
Do results differ for overweight people?
In adults carrying more fat mass the changes described generally differ, because a simultaneous fall in fat mass and rise in lean mass alters appearance more visibly than a rise in lean mass alone. A higher starting fat mass is widely understood to allow a rise in lean mass without a calorie surplus, since the energy held in fat mass can meet the cost of new lean tissue, and scale weight is commonly described as a poor guide in such adults, because the two changes move it in opposite directions.
Can I saturate my androgen receptors faster with a ‘loading phase’ of Rad-140?
Outside the published trials, a larger starting amount of RAD140 is described as filling androgen receptors sooner, and it is generally held not to saturate them in any way that brings more or quicker change in muscle tissue. The reason is that androgen receptor binding is widely understood as a reversible equilibrium rather than a store being filled: receptor occupancy at any moment depends on the concentration of compound present, binding and dissociation continue throughout, and no reserve of bound compound builds up in the receptor.
A loading dose (a larger initial amount) is generally held in classical pharmacology to raise circulating concentrations sooner, but the response in muscle tissue is commonly described as following the slower course of androgen-driven gene expression and protein synthesis, which an early surge in concentration is not held to accelerate. What a larger RAD140 dose is generally held to raise is exposure in tissues beyond skeletal muscle, with stronger suppression of endogenous testosterone production, lower HDL cholesterol and a higher risk of drug-induced liver injury as exposure rises.
How much of the gain is kept months after a cycle, with measured figures?
Outside the trial record, one set of accounts describes the rise in strength as largely retained months after exposure ends and the rise in size as partly retained, while another describes much of both lost within weeks. The two courses are incompatible, and no measured figure stands behind them: few accounts on either side give a dated follow-up measurement of body weight or strength, and the accounts that give a starting and a finishing weight almost never give a third weight months later, which is their most striking feature.
In those accounts scale weight falls first and fastest after exposure ends, an early fall attributed to fluid rather than to tissue; the larger and slower losses are attributed to a fall in dietary energy once the surplus ends, to reduced training, to a deliberate period of fat loss begun straight afterwards, or to incomplete natural testosterone recovery after RAD140, the return of endogenous testosterone production once exposure ends. Each of those factors would reduce lean mass on its own, so the attribution cannot be tested from within the accounts.
Accounts outside the published studies describe strength still rising into the second week after exposure ended, read there as evidence that the compound never accounted for the whole of the change in strength, and in descriptions beyond the trials body weight occasionally held steady until training stopped entirely, and fell only then. Both patterns point the same way: continued training rather than residual compound governs what remains after exposure ends.
What helps keep the gains after a cycle ends?
Beyond the trial data, the retention of muscle mass after exposure ends is described as resting on four measures, named far more often than anything pharmacological:
continued training at the same intensity
a diet high in protein and energy
adequate sleep
avoiding a deliberate period of fat loss immediately afterwards, described, outside the trial record, as the one that matters most, because a calorie deficit and a fall in androgen exposure arriving together are held to produce the losses of lean mass described in other accounts
In descriptions beyond the trials, medicines intended to restore endogenous hormone production also follow the end of exposure, and so do other compounds and testosterone therapy, used to bridge the interval, so that RAD140 with TRT runs on into one unbroken androgen period. What keeps lean mass afterwards is generally held to be continued training and sufficient dietary energy rather than any such bridging; lean mass kept through bridging is held to reflect the bridging compounds rather than RAD140, so what is retained shows only once every androgen has been withdrawn, and those accounts never reach that point, because in them the androgens never stop.
Those accounts leave aside the liver: what reversed after exposure ended in the published liver cases, and how long it took, is set out in the liver article rather than here.
What lab tests found in SARM products and urine samples
Two laboratory findings frame every before-and-after claim: a product sold as a SARM may hold less than its label states, and SARMs in urine samples often appeared alongside other anabolic compounds. The first comes from the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, which tested unapproved SARM products on sale and found them significantly under-dosed.
[Figure 1. SARMs found in Swedish urine samples. Of 542 male urine samples re-analysed by WADA-accredited methods in a Swedish laboratory, 20 held SARMs; RAD140 ranked second after LGD-4033. Over half of those positive samples held two or more SARMs and 40% also held anabolic steroids.]
The second comes from urine. Researchers re-analysed the male samples counted in the chart, from a Swedish healthcare laboratory, with anti-doping screening methods, the accredited chromatographic and mass-spectrometric assays of doping control, and detected SARMs in some of them; LGD-4033 (ligandrol) was the commonest, followed by RAD140 and by ostarine, like the other two a nonsteroidal selective androgen receptor modulator. The SARM-positive samples often held more than one compound, as the chart’s last row shows: most held two or more SARMs, and a substantial share also held anabolic-androgenic steroids (AAS), a class of compounds derived from testosterone and distinct from SARMs.
Twenty (4%) of the male urine samples (n = 542) were positive for SARMs, whereas none of the analyzed female samples (n = 100) contained any SARMs. The top three SARMs found were LGD-4033 followed by RAD140 and ostarine.
Both findings bear directly on a before-and-after photograph, because a described change may reflect a product with little of the labelled compound in it, or several compounds rather than one, and the image cannot tell these possibilities apart. Analytical data address exactly that problem: the RAD-140 for sale here, supplied for laboratory research, comes with batch and purity data for each lot, and the same documentation accompanies the other UK SARMs in stock.
Why do some people see little or no gain (non-responders)?
Among the effects described outside the trials, little or no change in some individuals after several weeks of exposure is attributed, in this order, to:
doubt about the product’s contents
unchanged diet
unchanged training
an expectation of change sooner than it could appear
In those accounts the ordering is itself telling, because it puts first the one explanation that calls for no reassessment of diet or training.
Outside the trial record, little or no change is also described as grounds for comparing products from different sources by the amount of change that followed each, though nothing in such a comparison shows what either product held; only analytical checks tell legit RAD 140 from a fake or under-strength product. Little or no change is described as the mark of a non-responder (a term found in a few accounts), while the term hyper-responder appears in fewer still, and neither has a measured definition behind it; in descriptions beyond the trials, the question of how a response to the compound could be recognised is raised directly, and the answers return to the same scale weight and mirror that produced the doubt.
Muscle and strength in rats and mice given RAD140
In animals RAD140 enlarged muscle fibres and preserved lean mass in some groups, and it did not improve grip strength, the peak force a rodent exerts against a pull bar. In young male rats, in the groups the chart below sets out, RAD140 without loading raised muscle fibre cross-sectional area significantly above vehicle control; given with functional overload (the surgical removal of synergists to load the plantaris muscle) it raised muscle weight markedly but no more than overload alone did. The question does RAD 140 increase muscle mass therefore turns on the stimulus, since the compound did so in unloaded rats and added nothing measurable to a strong loading stimulus.
[Figure 2. RAD140 and overload in rat muscle. In 40 young male rats over 14 days, RAD140 given alone enlarged plantaris fibres above vehicle, but when the muscle was surgically overloaded the drug added nothing measurable to overload alone, and bone was unchanged.]
The ageing studies divide by sex. Older male mice given 5 mg/kg/day, over the exposure set out in the table below, significantly preserved lean mass, while grip strength and fat mass were unaffected and females showed no such benefit; in young and adult female mice given 5 mg/kg over a longer exposure, strength did not improve either, and both mortality risk and the frailty index rose significantly. The measured effect, in other words, sits on fibre size and lean mass rather than on force production, and its direction depends on sex and age.
The earliest of the animal studies, in rats and monkeys, described RAD140 as potent and established its oral bioavailability, the fraction of an orally administered amount that reaches the circulation intact; its androgenic action in rats largely spared the prostate, the tissue selectivity that gives the class its name.
RAD140 muscle and strength in animal studies
Study
Animals
Exposure
Muscle and lean mass
Strength
Puskas 2025
Young male rats, 10 per group
RAD140 in drinking water, with or without plantaris overload; bone assessed at 14 days
Fibre cross-sectional area above vehicle without overload; with overload, muscle weight no different from overload alone
Not measured
Heinze 2025
Older mice, 21 male and 15 female
5 mg/kg/day for 6 weeks
Lean mass preserved in males (p = 0.024); no benefit in females
Adaptive potential lower in young mice (p = 0.040), not in adult mice (p = 0.688); frailty and mortality risk higher (p ≤ 0.042)
Torque no different from controls after 2 to 3 weeks of recovery (p ≥ 0.135)
Bone mineral density in the animal studies
The RAD-140 bone mineral density findings divide by sex in the same way as the lean mass results: six weeks of exposure preserved bone mineral density in older male mice (p = 0.004) but not in females. In young rats, micro computed tomography, high-resolution X-ray imaging of bone microarchitecture, detected no change in cortical or trabecular structural properties after 14 days, and that short exposure limits what the absence of change can show, because bone remodelling runs over intervals longer than two weeks.
What happens if you take RAD140 and do not train?
Outside the published trials, RAD140 administered without resistance training is said to bring little visible change, though almost no account gives that condition at first hand: the nearest report periods that began just as training ended. A few report a fuller appearance without lifting, which fits the fluid and glycogen content of muscle tissue rather than an increase in muscle mass, and among the effects described outside the trials intensive resistance work accompanies the change in nearly every case, so the untrained condition is largely unobserved.
What the animal data, case reports and photos cannot settle
The animal evidence is limited in size, in duration and in the animals studied: the rat study used ten animals per group, exposures across the three studies ran from 14 days to ten weeks, far shorter than the months needed to follow the retention of any change, and two of the studies used older or female mice, neither of which models a young, trained adult man.
The clinical evidence consists of case reports of single patients, one of whom was exposed to two compounds at once, so the injury cannot be assigned to either alone, and in a second case the authors describe the causal link as speculative. The urine survey drew on samples from one Swedish healthcare laboratory, so its figures describe the men whose samples reached that laboratory rather than any wider population. And the RAD 140 before and after accounts are self-reported, with changes that cannot be separated from the effects of diet, training and concurrent exposure to other compounds.
Six matters are therefore known from descriptions alone, and no published study among this article’s sources has measured any of them. These six matters are:
the size of the weight change
the share of it that is water
how soon change appears
the falls in strength
non-response
how much of any change is retained after exposure ends
RAD140 is not an approved medicine, and SARMs have been prohibited in sport at all times since 2008.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In young male rats, what did adding RAD140 to a strong loading stimulus (functional overload) do to muscle weight?
It added nothing significant beyond overload alone ✓
It roughly doubled the gain from overload alone
It reduced muscle weight compared with overload alone
It added a small but significant gain over overload
Without loading, RAD140 enlarged muscle fibres in young rats. With functional overload, muscle weight did not differ significantly from overload alone.
In older male mice given RAD140 for six weeks, what did the measurements show?
Raised grip strength, with lean mass unchanged
Preserved lean mass, with grip strength unchanged ✓
Preserved lean mass and raised grip strength
Lowered fat mass, with lean mass and grip unchanged
Older male mice kept more lean mass than controls, but grip strength was unaffected in either sex, so the measured effect was on mass rather than force.
In the Swedish survey of male urine samples, what did the SARM-positive samples typically contain?
Most held RAD140 and no other compound
Most held ostarine as the only SARM
Most held two or more different SARMs ✓
Most held a steroid but no other SARM
More than half of the SARM-positive samples held two or more SARMs, and 40% also held anabolic-androgenic steroids.
In the most severe published RAD140 liver case, what happened after the product was withdrawn?
Bilirubin fell to normal within two months
Bilirubin fell once corticosteroids were started
Bilirubin fell slowly over three to twelve months
Bilirubin kept rising despite corticosteroids ✓
This young man was exposed to a product with RAD-140 and andarine. His bilirubin kept rising after withdrawal and corticosteroids, and he needed plasmapheresis and intensive care.
Marie Korzepa is an honorary research fellow in the School of Sport, Exercise and Rehabilitation Sciences at the University of Birmingham. Marie specialises in muscle physiology and hypertrophy.
Reviewed by
Ailsa Gemmell· NHS Greater Glasgow and Clyde ·Last reviewed
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
MK-677 Reddit accounts describe increased appetite and deeper sleep early on, while trials recorded more fat-free mass and IGF-1 but no rise in strength.
What does RAD-140 do to the brain is known only from nerve-cell and rat studies, where it shielded neurons from injury about as well as testosterone did.
The first RAD 140 study tested the compound in 22 postmenopausal women with metastatic breast cancer, setting 100 mg daily as the highest tolerated dose.
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD 140 before and after: muscle, strength and what lasts
By Marie Korzepa, PhD, MSc · Reviewed by Ailsa Gemmell
Published · Updated · 22 min read
RAD 140 before and after in brief
Every RAD 140 before and after account links RAD140 with a rise in body weight and strength, and no study has measured how much of that rise is muscle tissue or how much of it survives the end of exposure. RAD140 is a selective androgen receptor modulator (SARM), a nonsteroidal compound acting on the androgen receptor inside cells.
The accounts have a shape of their own: self-reported body weights, photographs and lifted loads, recorded while a calorie surplus, training or other compounds were in play, so no part of the change can be assigned to RAD140 alone. The measured record is smaller and different. Animal studies show the compound enlarging muscle fibres in rats and, in older male mice, preserving fat-free mass, the body’s non-fat tissue measured as lean mass. Case reports, published accounts of single patients, describe severe drug-induced liver injury after weeks to months of exposure.
Behind both sits the preclinical work that introduced the compound later known as vosilasarm, characterised it in rats and monkeys, and described it as potent and orally bioavailable. That history, and the RAD 140 mechanism of action it first set out, is the background to every later measurement, and the question does RAD 140 work comes down to whether the measured data bear out the changes the accounts describe.
This article sets the animal measurements, the case reports and the laboratory analyses of products and urine samples beside the self-reported accounts, for skeletal muscle mass, strength and what remains after exposure ends. Dose and co-administration with other compounds have their own pages.
Patients treated in hospital after muscle-building supplements
Six published case reports belong beside the photographs, and the table below holds them: young men, products containing RAD140 and sold as muscle-building supplements, hospital after weeks to months of exposure, and in every case the liver. The briefest exposure in the table belongs to the first man, who presented with cholestatic liver injury marked by impaired bile flow; a biopsy supported the diagnosis of RAD-140 liver injury, and his total bilirubin rose to the peak the table gives.
Six published RAD140 liver cases
The third man in the table, exposed for longer, developed jaundice together with raised liver enzymes (ALT, AST, alkaline phosphatase), and ultrasound showed fatty liver. The fourth man, exposed for longer still, reached the total bilirubin peak the table gives for him.
The most severe case followed a supplement containing RAD-140 and andarine (S-4), another nonsteroidal SARM: in intensive care it brought pancreatitis and acute kidney injury and required plasmapheresis, the exchange of blood plasma to remove circulating substances. Other organs appear in the series too, possible acute myocarditis, inflammation of the cardiac muscle, in a young man, and splenic rupture in a 54-year-old man exposed to RAD-140 and MK-677 (ibutamoren, a growth hormone secretagogue), though its authors call that link speculative. LiverTox, the National Institutes of Health database of drug-induced liver injury monographs, lists the cholestatic pattern for the SARM class. What these reports record is what exposure to such products brought for these patients, and that is why they stand next to the photographs.
What before-and-after reports describe for muscle and body weight
Outside the published trials, no question recurs through the before-and-after accounts of RAD 140 more than how much of a rise in body weight is skeletal muscle mass. Most claims of a “RAD 140 muscle gain” rest on such reports, which differ widely in the cause they assign to the change. Two of the changes they describe have names: vascularity, the greater visibility of superficial veins beneath thin subcutaneous fat, and body recomposition, a fall in fat mass alongside a rise in lean mass while energy consumption stays unchanged. They describe these changes:
In those accounts the claims rest on photographs that need their own reading. A RAD 140 transformation is typically documented in mirror shots taken at different times of day, and the images differ in lighting, in pose and in pump, the temporary swelling of muscle tissue after training; accounts collected from RAD-140 Reddit and YouTube describe the same physique as looking substantially different within a single day.
How much of the weight gained is muscle and how much is water?
Beyond the trial data, a substantial part of the weight gained is described as food and fluid rather than muscle tissue, and the fluid as water retention (held in the tissues and the circulation rather than in muscle protein); such retention is described as showing visibly after days of a high-carbohydrate diet, with scale weight changing within a week.
In descriptions beyond the trials, body weight sometimes rises with no visible change at all. RAD-140 is described, outside the trial record, as bringing a leaner, drier gain than LGD-4033 and other SARMs, which implies less fluid and so a smaller share of the weight that disappears afterwards; a fall in scale weight soon after exposure ends is widely described, and fluid leaving first is the explanation given.
Among the effects described outside the trials the measures relied on are scale weight and the mirror, and neither can settle the composition of the weight itself, because neither separates the components that move together with muscle mass:
In those accounts one detailed exception cites a DEXA scan, a dual-energy X-ray absorptiometry body-composition measurement, which partitioned the weight gained so that muscle tissue made up the smaller part. The exception proves the rule: the accounts of SARM RAD140 found most often give a single figure for body weight and nothing else.
How much stronger did you get?
For a trained adult the rise in strength with a SARM is generally held to be modest in absolute terms, roughly a few repetitions or one load increment per lift, and to arrive within the first weeks rather than months; accounts outside the published studies describe it as the earliest change.
The usual answer to how strong is RAD 140 takes that early rise apart. Much of it is held to be neural and technical, because better motor-unit recruitment, familiarity with the lift and confidence under load all follow training alone. A second part is attributed to recovery, because delayed-onset muscle soreness (DOMS), which peaks a day or two after unfamiliar loading, settles sooner and lets training volume rise, which is widely held to raise strength by itself. A third part is held to come from the fluid and glycogen content of muscle tissue, which supports force output while present and leaves when exposure ends.
Why does strength drop for some people on RAD140?
Outside the trial record, a fall in strength is described as a consequence of testosterone suppression, the decline in endogenous testosterone production that follows exposure to an androgen receptor agonist and that the human trial data on RAD140 and testosterone record. The fall is described as arriving partway through a period of exposure rather than at its start, and as coming with tiredness, poor sleep, lethargy, cramping and low drive; the attribution to suppression rests on the descriptions themselves, not on any measurement.
In those accounts the same drop has other explanations as well, four causes in all:
How soon the changes are described
Accounts outside the published studies describe a change in strength within the first days of exposure and a fuller appearance within the first weeks. Most of them pair a photograph from before exposure with one at 1 month of RAD 140, so the interval they fix reflects when change is looked for rather than when it occurs.
Outside the trial record, testolone is described as producing visible change in the shoulders and upper arms before other regions, and the one-month pairing is built around that early shift, though not every account follows that course; among the effects described outside the trials, the absence of any visible change by the third week recurs often enough to raise a question of its own, whether anything is to be expected within three weeks.
In those accounts rapid early change is sometimes put down not to the compound but to skeletal muscle memory, the faster regain of previously held muscle mass after a period without training. The accounts in question describe a return to training after a break, following an earlier period of greater lean mass, and they are the hardest of all to interpret, because the rate of regain after detraining is steep without any exposure to the compound.
Could I have made these gains without RAD-140?
Yes, as a rule. Such a change is generally held to be achievable without RAD-140: a food surplus, progressive training and the faster regain of earlier muscle mass explain most of what is described over a typical eight to twelve weeks of exposure, and two starting points add to them. The five are:
With a surplus and progressive overload both present, a rise of one to two pounds a month in lean mass is generally held to be achievable in a trained adult male without any compound, considerably more in an untrained one, and more again in previously trained muscle tissue. Beyond the trial data, the periods of exposure described most often begin from one of the last two starting points, the two that carry the highest baseline rate of change.
Do results differ for overweight people?
In adults carrying more fat mass the changes described generally differ, because a simultaneous fall in fat mass and rise in lean mass alters appearance more visibly than a rise in lean mass alone. A higher starting fat mass is widely understood to allow a rise in lean mass without a calorie surplus, since the energy held in fat mass can meet the cost of new lean tissue, and scale weight is commonly described as a poor guide in such adults, because the two changes move it in opposite directions.
Can I saturate my androgen receptors faster with a ‘loading phase’ of Rad-140?
Outside the published trials, a larger starting amount of RAD140 is described as filling androgen receptors sooner, and it is generally held not to saturate them in any way that brings more or quicker change in muscle tissue. The reason is that androgen receptor binding is widely understood as a reversible equilibrium rather than a store being filled: receptor occupancy at any moment depends on the concentration of compound present, binding and dissociation continue throughout, and no reserve of bound compound builds up in the receptor.
A loading dose (a larger initial amount) is generally held in classical pharmacology to raise circulating concentrations sooner, but the response in muscle tissue is commonly described as following the slower course of androgen-driven gene expression and protein synthesis, which an early surge in concentration is not held to accelerate. What a larger RAD140 dose is generally held to raise is exposure in tissues beyond skeletal muscle, with stronger suppression of endogenous testosterone production, lower HDL cholesterol and a higher risk of drug-induced liver injury as exposure rises.
How much of the gain is kept months after a cycle, with measured figures?
Outside the trial record, one set of accounts describes the rise in strength as largely retained months after exposure ends and the rise in size as partly retained, while another describes much of both lost within weeks. The two courses are incompatible, and no measured figure stands behind them: few accounts on either side give a dated follow-up measurement of body weight or strength, and the accounts that give a starting and a finishing weight almost never give a third weight months later, which is their most striking feature.
In those accounts scale weight falls first and fastest after exposure ends, an early fall attributed to fluid rather than to tissue; the larger and slower losses are attributed to a fall in dietary energy once the surplus ends, to reduced training, to a deliberate period of fat loss begun straight afterwards, or to incomplete natural testosterone recovery after RAD140, the return of endogenous testosterone production once exposure ends. Each of those factors would reduce lean mass on its own, so the attribution cannot be tested from within the accounts.
Accounts outside the published studies describe strength still rising into the second week after exposure ended, read there as evidence that the compound never accounted for the whole of the change in strength, and in descriptions beyond the trials body weight occasionally held steady until training stopped entirely, and fell only then. Both patterns point the same way: continued training rather than residual compound governs what remains after exposure ends.
What helps keep the gains after a cycle ends?
Beyond the trial data, the retention of muscle mass after exposure ends is described as resting on four measures, named far more often than anything pharmacological:
In descriptions beyond the trials, medicines intended to restore endogenous hormone production also follow the end of exposure, and so do other compounds and testosterone therapy, used to bridge the interval, so that RAD140 with TRT runs on into one unbroken androgen period. What keeps lean mass afterwards is generally held to be continued training and sufficient dietary energy rather than any such bridging; lean mass kept through bridging is held to reflect the bridging compounds rather than RAD140, so what is retained shows only once every androgen has been withdrawn, and those accounts never reach that point, because in them the androgens never stop.
Those accounts leave aside the liver: what reversed after exposure ended in the published liver cases, and how long it took, is set out in the liver article rather than here.
What lab tests found in SARM products and urine samples
Two laboratory findings frame every before-and-after claim: a product sold as a SARM may hold less than its label states, and SARMs in urine samples often appeared alongside other anabolic compounds. The first comes from the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, which tested unapproved SARM products on sale and found them significantly under-dosed.
The second comes from urine. Researchers re-analysed the male samples counted in the chart, from a Swedish healthcare laboratory, with anti-doping screening methods, the accredited chromatographic and mass-spectrometric assays of doping control, and detected SARMs in some of them; LGD-4033 (ligandrol) was the commonest, followed by RAD140 and by ostarine, like the other two a nonsteroidal selective androgen receptor modulator. The SARM-positive samples often held more than one compound, as the chart’s last row shows: most held two or more SARMs, and a substantial share also held anabolic-androgenic steroids (AAS), a class of compounds derived from testosterone and distinct from SARMs.
Both findings bear directly on a before-and-after photograph, because a described change may reflect a product with little of the labelled compound in it, or several compounds rather than one, and the image cannot tell these possibilities apart. Analytical data address exactly that problem: the RAD-140 for sale here, supplied for laboratory research, comes with batch and purity data for each lot, and the same documentation accompanies the other UK SARMs in stock.
Why do some people see little or no gain (non-responders)?
Among the effects described outside the trials, little or no change in some individuals after several weeks of exposure is attributed, in this order, to:
In those accounts the ordering is itself telling, because it puts first the one explanation that calls for no reassessment of diet or training.
Outside the trial record, little or no change is also described as grounds for comparing products from different sources by the amount of change that followed each, though nothing in such a comparison shows what either product held; only analytical checks tell legit RAD 140 from a fake or under-strength product. Little or no change is described as the mark of a non-responder (a term found in a few accounts), while the term hyper-responder appears in fewer still, and neither has a measured definition behind it; in descriptions beyond the trials, the question of how a response to the compound could be recognised is raised directly, and the answers return to the same scale weight and mirror that produced the doubt.
Muscle and strength in rats and mice given RAD140
In animals RAD140 enlarged muscle fibres and preserved lean mass in some groups, and it did not improve grip strength, the peak force a rodent exerts against a pull bar. In young male rats, in the groups the chart below sets out, RAD140 without loading raised muscle fibre cross-sectional area significantly above vehicle control; given with functional overload (the surgical removal of synergists to load the plantaris muscle) it raised muscle weight markedly but no more than overload alone did. The question does RAD 140 increase muscle mass therefore turns on the stimulus, since the compound did so in unloaded rats and added nothing measurable to a strong loading stimulus.
The ageing studies divide by sex. Older male mice given 5 mg/kg/day, over the exposure set out in the table below, significantly preserved lean mass, while grip strength and fat mass were unaffected and females showed no such benefit; in young and adult female mice given 5 mg/kg over a longer exposure, strength did not improve either, and both mortality risk and the frailty index rose significantly. The measured effect, in other words, sits on fibre size and lean mass rather than on force production, and its direction depends on sex and age.
The earliest of the animal studies, in rats and monkeys, described RAD140 as potent and established its oral bioavailability, the fraction of an orally administered amount that reaches the circulation intact; its androgenic action in rats largely spared the prostate, the tissue selectivity that gives the class its name.
RAD140 muscle and strength in animal studies
Bone mineral density in the animal studies
The RAD-140 bone mineral density findings divide by sex in the same way as the lean mass results: six weeks of exposure preserved bone mineral density in older male mice (p = 0.004) but not in females. In young rats, micro computed tomography, high-resolution X-ray imaging of bone microarchitecture, detected no change in cortical or trabecular structural properties after 14 days, and that short exposure limits what the absence of change can show, because bone remodelling runs over intervals longer than two weeks.
What happens if you take RAD140 and do not train?
Outside the published trials, RAD140 administered without resistance training is said to bring little visible change, though almost no account gives that condition at first hand: the nearest report periods that began just as training ended. A few report a fuller appearance without lifting, which fits the fluid and glycogen content of muscle tissue rather than an increase in muscle mass, and among the effects described outside the trials intensive resistance work accompanies the change in nearly every case, so the untrained condition is largely unobserved.
What the animal data, case reports and photos cannot settle
The animal evidence is limited in size, in duration and in the animals studied: the rat study used ten animals per group, exposures across the three studies ran from 14 days to ten weeks, far shorter than the months needed to follow the retention of any change, and two of the studies used older or female mice, neither of which models a young, trained adult man.
The clinical evidence consists of case reports of single patients, one of whom was exposed to two compounds at once, so the injury cannot be assigned to either alone, and in a second case the authors describe the causal link as speculative. The urine survey drew on samples from one Swedish healthcare laboratory, so its figures describe the men whose samples reached that laboratory rather than any wider population. And the RAD 140 before and after accounts are self-reported, with changes that cannot be separated from the effects of diet, training and concurrent exposure to other compounds.
Six matters are therefore known from descriptions alone, and no published study among this article’s sources has measured any of them. These six matters are:
RAD140 is not an approved medicine, and SARMs have been prohibited in sport at all times since 2008.
Check what you remember
4 questions on this article; the right answer is marked.
Without loading, RAD140 enlarged muscle fibres in young rats. With functional overload, muscle weight did not differ significantly from overload alone.
Older male mice kept more lean mass than controls, but grip strength was unaffected in either sex, so the measured effect was on mass rather than force.
More than half of the SARM-positive samples held two or more SARMs, and 40% also held anabolic-androgenic steroids.
This young man was exposed to a product with RAD-140 and andarine. His bilirubin kept rising after withdrawal and corticosteroids, and he needed plasmapheresis and intensive care.
Marie Korzepa, PhD, MSc · University of Birmingham
Honorary Research Fellow
Marie Korzepa is an honorary research fellow in the School of Sport, Exercise and Rehabilitation Sciences at the University of Birmingham. Marie specialises in muscle physiology and hypertrophy.
Ailsa Gemmell · NHS Greater Glasgow and Clyde · Last reviewed
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Related Posts
MK-677 Reddit: discussions weighed against the trials
MK-677 Reddit accounts describe increased appetite and deeper sleep early on, while trials recorded more fat-free mass and IGF-1 but no rise in strength.
What does RAD-140 do to the brain? Neuron and rat studies
What does RAD-140 do to the brain is known only from nerve-cell and rat studies, where it shielded neurons from injury about as well as testosterone did.
RAD 140 study: what the breast-cancer trials found
The first RAD 140 study tested the compound in 22 postmenopausal women with metastatic breast cancer, setting 100 mg daily as the highest tolerated dose.
Ostarine for cutting: lean mass and fat loss in the trials
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.